MDM2 and acute myeloid leukemia: In addition to the challenges of acquired resistance caused by p53 mutation for MDM2–p53 disruptors (41, 42), non-mutational wtp53 dysfunction that occurs broadly in AML poses another challenge to these p53-based inhibitors (43).